This week's biggest % winners & losers : May 9 - 13, 22 (wk 19)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: BHVN (140.96 +56.19%), ITCI (58.96 +27.62%), FOLD (7.56 +20.57%), EOLS (13.16 +19.64%), FGEN (9.92 +17.95%), OPK (3.00 +14.5%), TCDA (9.13 +14.27%), PRGO (36.89 +13.56%)
• Industrials: RBA (61.97 +18.44%), TREX (62.57 +12.8%), ENR (33.27 +10.97%)
• Consumer Discretionary: HRB (32.29 +27.56%), NDLS (6.49 +16.94%), MBUU (59.81 +15.26%)
• Information Technology: APPN (57 +19.95%)
• Consumer Staples: THS (38.85 +27.21%), NOMD (21 +18.98%), BRFS (2.74 +14.64%)

This week's top % losers

• Healthcare: TXMD (3.07 -60.01%), BHC (10.86 -32.29%), EVLO (1.67 -32.11%), GDRX(8.90  -30.14%), SIBN (12.46 -27.88%), INO (1.99 -25.38%), FLDM (2.21 -25.08%), CRBP (0.22 -24.61%), RYTM (3.27 -23.6%), FIXX (1.43 -23.53%)
• Industrials: KRNT (44.51 -30.66%)
• Consumer Discretionary: PRTY (1.43 -53.43%), TUP (7.28 -26.74%), EYE (26.13 -26.31%)
• Information Technology: DM (1.89 -52.63%), U (39.10  -31.81), AVYA (6.41 -26.72%)
• Energy:  MTRX (5.01 -23.39%)

===Inovio Pharma (INO) reported earnings on Tue 10 May 22 (a/h)

•  Inovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO

Inovio Pharma misses by $0.03, misses on revs

• Reports Q1 (Mar) loss of $0.36 per share, $0.03 worse than the S&P Capital IQ Consensus of ($0.33); revenues fell 46.4% year/year to $0.2 mln vs the $0.66 mln S&P Capital IQ Consensus.

May 10 (Reuters) - Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell.

The decision on the trial comes after emerging global data showed a lower incidence of severe COVID cases, which would lead to an increase in trial size and costs, the company said.

It would now focus on developing its vaccine candidate, INO-4800, as a heterologous booster.

The biotechnology company's new strategy also comes with a change at the helm, with Jacqueline Shea taking over as CEO, effective immediately. She replaces current CEO and co-founder Joseph Kim.

The change at the top comes at a crucial stage when the company has fallen behind in the COVID vaccine race.

In November last year, Inovio resumed the late-stage trial of its COVID vaccine in the United States after being on clinical hold for 14 months. The FDA in late 2020 had halted the study as it sought more data, including details on a delivery device used to inject genetic material into cells.

This week's biggest % winners & losers: March 9 - 13, 20 (wk 11)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: OSUR (7.54 +27.36%), VAPO (12.54 +22.46%), PINC (34.95 +21.02%), TBIO (8.93 +20.68%), EBS (68.76 +17.24%), SLDB (3.72 +16.98%)
• Industrials: AFI (2.66 +39.27%)
• Consumer Discretionary: GME (4.59 +17.09%), LRN (23.94 +16.78%)
• Information Technology: CY (23.11 +41.17%)
• Energy: DO (3.76 +82.52%), GPOR (0.89 +77.43%), EQT (9.53 +49.14%), SWN (1.77 +35.11%), FRO (9.35 +32.81%), CNX (6.72 +30.74%), EXTN (8.5 +29.18%), DHT (6.6 +28.16%), STNG (20.5 +25%), EURN (10.49 +22.98%)

This week's top % losers

• Healthcare: TVTY (4.36 -60.04%), TLRY (4.03 -59.83%), INO (7.20  -48.90%)
• Consumer Discretionary: NCLH (11.1 -59.04%), RCL (32.33  -50.27%)
• Financials: FMO (1.77 -64.1%), GMZ (1.45 -62.14%), JMF (2.02 -60.08%)
• Energy: CLB (8.49 -64.39%), CDEV (0.56 -63.28%), PVAC (4.1 -62.35%), SLCA (1.26 -61.59%), NBR (0.37 -61.52%), ECA (3.09 -61.08%), APA (8.07 -61.01%), OII (3.23 -60.47%), FTSI (0.28 -60.23%), MTDR (2.64 -59.69%), NBLX (4.86 -59.3%), OIS (2.42 -59.19%)
• Materials: JNUG (4.47  -92.90%), NUGT (6.76  -79.07%) 

Citron Research: Inovio Pharma (INO) going back to $2

• 3/9/20: Citron Research says INO going to $2:

• 5 weeks later:

Inovio co-founder David Weiner spoke on Bloomberg TV

10 days later; April 27, 20

Long trade : Inovio Pharma (INO) +220%

• Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April
• The company said it’s accelerating the timeline for development of a vaccine to treat the coronavirus COVID-19 and expects to start human trials in the U.S. next month.

 

This week's biggest % winners & losers: March 2 - 6, 20 (wk 10)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: INO (14.09 +229.21%), FTSV (94.35  +62.67), OPK (2.32 +54.67%), KPTI (25.02 +53.12%), OMER (18.08 +51.81%), BCRX (4.11 +37%), FIXX (20.78 +29.88%), RCUS (19.28 +26.68%), ANAB (18.23 +21.94%), IOVA (38.85 +18.05%)
• Materials: AU (21.06 +20.69%)
• Industrials: AVAV (61.15 +18.99%)
• Energy: EXTN (6.58 +29.02%)
• Consumer Staples: BJ (23.91 +24.14%), RAD (16.15 +18.58%)

This week's top % losers

• Healthcare: SGRY (10.76 -34.47%)
• Consumer Discretionary: AGS (6.21 -35.91%), HUD (6.23 -33.08%), ERI (33.65 -32.94%), RRGB (18.5 -32.73%)
• Energy: CPE (1.3 -42.73%), SM (3.82 -41.86%), KOS (1.95 -36.07%), QEP (1.44 -36%), CDEV (1.52 -35.86%), TELL (1.21 -32.78%), DO (2.06 -32.46%)

=Inovio Pharma (INO) : positive HIV vaccine results

Inovio Pharma announces that its HIV vaccine, PENNVAX-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study(4.73 )

More comprehensive immune analyses demonstrated that PENNVAX-GP (plus IL-12) generated HIV-specific CD4+ T cell and binding antibody response rates close to 100% when delivered with either CELLECTRA intramuscular or intradermal devices.

• For instance, 96% (26 of 27) of participants receiving PENNVAX-GP and IL-12 via the IM route demonstrated a CD4+ T cell response while the same percentage (96% or 27 of 28) of participants receiving the vaccine formulation via ID administration also displayed anti-HIV CD4+ T cell responses -- even though those vaccinated via intradermal administration received 1/5th the total dose compared to those vaccinated via the intramuscular device.
• The new data from subjects followed for a full one year of the study showed that the immune responses were maintained in most subjects at month 12 (or six months after the last dose) as evidenced by the durability of activated T cells as well as the magnitude of responder rates. Notably, the percentage of patients who had CD8+ T cell responses immediately after the last dose stayed the same or even increased slightly over the 6 month follow up period, clearly demonstrating durable vaccine-generated memory responses.

Inovio Pharmaceuticals (INO) announces pricing of public offering of common stock

 

Inovio Pharmaceuticals, Inc. (INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share.  The gross proceeds to Inovio from the offering are expected to be $75.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Inovio.  All of the shares are being offered by Inovio.  The offering is expected to close on July 25, 2017, subject to customary closing conditions.  In addition, Inovio has granted the underwriters a 30‑day option to purchase up to 1,875,000 additional shares of its common stock on the same terms and conditions.

Inovio anticipates using the net proceeds from this offering for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and other business development activities.

******

Inovio sparked a rally in May after announcing positive early-stage results for its experimental HIV vaccine. More recently, news that the FDA would allow the company's only late-stage clinical trial to continue lifted the stock a bit further.

Beyond these two, the company has more candidates in clinical-stage development than most biotechs several times its size, which isn't cheap. Inovio recorded research and development expenses of $24.5 million during the first three months of the year alone.

The company received about $10.4 million in the form of grants and collaboration revenue, but it still burned through $23.1 million during the first quarter. Adding the likely proceeds of this upcoming share offering to whatever remains of the $100.7 million in cash and short-term investments on its balance sheet at the end of March will lengthen its runway somewhat. Until Inovio has an application ready to submit to the FDA, though, investors should remain braced for more share offerings ahead.

Inovio Pharma (INOV)'s HIV vaccine

• Announces that its HIV vaccine, PENNVAX-GP, 'produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine'

** charts after announcement **

 

Inovio Pharma announces that its HIV vaccine, PENNVAX-GP, 'produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine' :
 ....announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV. These preliminary results are from a study supported by the HIV Vaccine Trials Network (:HVTN) and the National Institute of Allergy and Infectious Diseases (:NIAID), part of the National Institutes of Health (:NIH) in collaboration with Inovio.

** charts before announcement ** 

  

Inovio Pharma (INO) reported earnings on Wed 15 March 2017 (a/h)

** charts before earnings **

  

** charts after earnings **

Inovio Pharma misses by $0.02, beats on revs; updates pipeline :

• Reports Q4 (Dec) loss of $0.35 per share, $0.02 worse than the Capital IQ Consensus of ($0.33); revenues rose 44.1% year/year to $8.5 mln vs the $5.21 mln Capital IQ Consensus.
• Dr. J. Joseph Kim, President and CEO, said: "In 2016 Inovio made significant progress on all three focuses of its Vision 2020 plan, which are HPV-related precancer, immuno-oncology, and infectious diseases, with notable data, multiple trial completions, progressive clinical study preparations, and multiple valuable collaborations and funding agreements. In 2017 we expect to report immune response data from clinical studies in six different diseases; the initiation of our phase 3 study of cervical dysplasia and two immuno-oncology combination studies, one by MedImmune and one by Inovio; and additional business development steps. We look forward to a highly productive year in advancing our unique immunotherapy platform and products."
• Corporate Updates
  • Inovio is planning to launch a phase 2 clinical study in 2017 for another HPV-related disease, vulvar intraepithelial neoplasia.
  • Completed enrollment of 94 subjects in the phase 1 study of our PENNVAX-GP HIV immunotherapy. After completing extensive immunogenicity analyses, they expect to report data in 2H 2017.

Long trade : INO (1/16 & 4/16)

(1/16)

(4/16)

Long trade : INO (12/15)

• Followed by a big drop in January: